Efficacy and safety of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria (PNH) after 15 years steroids treatment: a case report description
Background Paroxysmal Nocturnal Hemoglobinuria (PNH) pathogenesis is due to acquired lack of glycosylphosphatidylinositol-anchored protein complement regulatory proteins (CD55 and CD59) and intra-extravascular hemolysis. Eculizumab is a monoclonal antibody binding complement protein 5 (C5 receptor C...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bulgarian Association of Young Surgeons
2019-11-01
|
| Series: | International Journal of Medical Reviews and Case Reports |
| Subjects: | |
| Online Access: | http://www.mdpub.net/index.php?fulltxt=63629&fulltxtj=172&fulltxtp=172-1567273780.pdf |